Medical Rationale
Major depressive disorder produces chronic fatigue through neuroinflammatory mechanisms that extend beyond subjective tiredness. Depression elevates pro-inflammatory cytokines (IL-1, IL-6, TNF-alpha) that cross the blood-brain barrier and disrupt mitochondrial energy metabolism in neurons, producing objective cellular fatigue. The HPA-axis dysregulation in MDD (cortisol elevation or blunted cortisol response) disrupts the circadian energy regulation system. Non-restorative sleep from depression-related insomnia prevents normal physical recovery. Neuroimaging shows reduced metabolism in the basal ganglia and prefrontal cortex in depressed patients with fatigue — suggesting a distinct neurobiological substrate beyond the depression itself. When fatigue persists despite adequate depression treatment, it represents a separately ratable condition.
Key Studies
Dantzer R et al. (2008) Nat Rev Neurosci (cytokine-induced fatigue); Nunes EJ et al. (2013) Neurosci Biobehav Rev (basal ganglia and effort-related fatigue in depression); Targum SD & Fava M (2011) Innov Clin Neurosci (residual fatigue in treated depression).
Filing Tips
Document persistent fatigue despite antidepressant treatment (residual fatigue after depression remission is well-documented). Fatigue severity scales and functional assessments. Rheumatology or internal medicine evaluation to rule out other causes and diagnose CFS. Psychiatrist nexus letter addressing the neuroinflammatory mechanism connecting MDD to chronic fatigue as a distinct condition. VA rates CFS under DC 6354 — separately from the MDD rating under DC 9434.